ASCO: Endocrine Tx Noninferior for HR & #43;, HER2 & #8722; Breast Cancer
MONDAY, June 4, 2018 -- For women with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer with a midrange 21-gene recurrence score, adjuvant endocrine therapy is noninferior to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2018 Category: Pharmaceuticals Source Type: news

Genetic Test Can Rule Out Chemo Use in Early Breast Cancer
(MedPage Today) -- Most women can get endocrine therapy alone based on Oncotype Dx results (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 3, 2018 Category: Hematology Source Type: news

Adding Ribociclib Improves PFS in Premenopausal Breast Cancer
Dave LevitanJun 1, 2018Ribociclib plus endocrine therapy resulted in improved progression-free survival in premenopausal women with HR-positive, HER2-negative advanced breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 1, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Surgery benefits older women with breast cancer
(Wiley) In a BJS (British Journal of Surgery) analysis of 18,730 older patients with estrogen receptor-positive breast cancer in the UK, the risk of dying from breast cancer was greater in patients treated with primary endocrine therapy than in those who received surgery. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 23, 2018 Category: Cancer & Oncology Source Type: news

Improving Adherence to Endocrine Therapy in Women With HR-Positive Breast Cancer
Here, we discuss how to improve adherence to endocrine therapy in women with HR-positive breast cancer, as well as the side effects and the reasons for discontinuation. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Charles L. Shapiro, MD Julia P. Brockway, MD Tags: Breast Cancer Oncology Journal Source Type: news

Prognostic Tool Can Guide Extended Endocrine Therapy in ER+ Breast Cancer
A simple prognostic tool could be used to identify patients with HR-positive breast cancer who underwent 5 years of endocrine treatment and who might be at higher risk of late distant recurrence. (Source: CancerNetwork)
Source: CancerNetwork - April 24, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer SiteTerms/www.cannabissciencetech.com/News Source Type: news

Novel Study of Endocrine Therapy-Induced Hair Loss Novel Study of Endocrine Therapy-Induced Hair Loss
Breast cancer patients are at risk for alopecia with endocrine therapy, but hair growth can often be restored with topical minoxidil.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 17, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Alopecia caused by hormone therapy in breast cancer
A study, published inJAMA Dermatology, reports that endocrine therapy-induced alopecia in breast cancer patients is mechanistically similar to androgenetic alopecia.Medical Xpress (Source: Society for Endocrinology)
Source: Society for Endocrinology - April 13, 2018 Category: Endocrinology Source Type: news

Endocrine Therapy - Induced Alopecia Seen in Breast Cancer
92 percent had grade 1 severity alopecia with endocrine tx; pattern similar to androgenetic alopecia (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 12, 2018 Category: Cancer & Oncology Tags: Dermatology, Gynecology, Oncology, Pharmacy, Journal, Source Type: news

Endocrine Therapy-Induced Alopecia Seen in Breast Cancer
THURSDAY, April 12, 2018 -- For patients with breast cancer, endocrine therapy-induced alopecia (EIA) has a pattern that is similar to androgenetic alopecia, according to a study published online April 11 in JAMA Dermatology. Azael Freites-Martinez,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 12, 2018 Category: Pharmaceuticals Source Type: news

The use of immunotherapy to treat metastatic breast cancer
(Bentham Science Publishers) The Authors review immunotherapy attempts to treat metastatic breast cancer. They include a) the addition of cytokines to endocrine therapy, b) monoclonal antibodies associated to chemotherapy and c) vaccination. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 19, 2018 Category: Cancer & Oncology Source Type: news

Optimal Duration of Endocrine Therapy for Breast Cancer Optimal Duration of Endocrine Therapy for Breast Cancer
According to a new study, five years of extended adjuvant letrozole for early breast cancer was not superior to 2.5 years.Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 13, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Late Recurrence in ER- Positive Breast Cancer: Banking on Biomarkers Late Recurrence in ER- Positive Breast Cancer: Banking on Biomarkers
Evaluation of biomarkers after 5 years of standard therapy for hormone-positive breast cancer may help determine those at risk for recurrence and those who may need further endocrine therapy.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 17, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Why Is Neoadjuvant Endocrine Therapy Underused in Breast Cancer? Why Is Neoadjuvant Endocrine Therapy Underused in Breast Cancer?
Experts discuss the evidence behind neoadjuvant endocrine therapy for early-stage breast cancer and obstacles to wider use of this treatment strategy.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 20, 2017 Category: Consumer Health News Tags: Hematology-Oncology Article Source Type: news

Only 2 Years of Extended Anastrozole Needed in Breast Cancer Only 2 Years of Extended Anastrozole Needed in Breast Cancer
After an initial 5 years of endocrine therapy in postmenopausal cancer, a further 2 years of the aromatase inhibitor is sufficient, instead of another 5 years, suggest new results.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 8, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Ribociclib Effective in Younger Breast Cancer Patients Too Ribociclib Effective in Younger Breast Cancer Patients Too
In premenopausal women with HR-positive, HER2-negative advanced breast cancer, the CDK4/6 inhibitor plus endocrine therapy dramatically improves progression-free survival compared with endocrine therapy alone.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 8, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Contrast-enhanced digital mammography comparable to breast MRI after therapy or chemo
(Mayo Clinic) Contrast-enhanced digital mammography is comparable to breast MRI in evaluating residual breast cancer after neoadjuvant endocrine therapy or chemotherapy, according to the results of a study presented by Mayo Clinic researchers today at the 2017 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 6, 2017 Category: Cancer & Oncology Source Type: news

Intermittent Letrozole Similar to Continuous Administration for Extended Breast Cancer Therapy
Taking temporary treatment breaks from letrozole following endocrine therapy for breast cancer is associated with similar disease-free survival as taking letrozole continuously, according to... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 20, 2017 Category: Primary Care Source Type: news

Breast Cancer Recurrence Still a Threat Decades After Completing 5 Years' Endocrine Therapy
Women with estrogen-receptor (ER)-positive, early-stage breast cancer who receive 5 years of adjuvant endocrine therapy are still at risk for recurrence up... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 9, 2017 Category: Primary Care Source Type: news

' Unrelenting': 20-Year Recurrence Risks in Breast Cancer'Unrelenting': 20-Year Recurrence Risks in Breast Cancer
Clinicians have new long-term data to use in discussions with patients with estrogen receptor-positive breast cancer who have been treated with 5 years of endocrine therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 8, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA approves new treatment for certain advanced or metastatic breast cancers
The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient ’s hormones (endocrine therapy). (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 28, 2017 Category: American Health Source Type: news

Abemaciclib: First-Line CDK4/6 Inhibitor for Breast Cancer Abemaciclib: First-Line CDK4/6 Inhibitor for Breast Cancer
Abemaciclib, the third CDK4/6 inhibitor, in combination with endocrine therapy shows significant benefit for the first-line treatment of HR+ HER2- advanced breast cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Abemaciclib initial therapy improves outcome in endocrine-sensitive advanced breast cancer
(European Society for Medical Oncology) The results of the MONARCH 3 trial, presented at the ESMO 2017 Congress in Madrid (1), showed that adding the cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib to endocrine therapy improved progression-free survival compared to endocrine therapy alone in the total study population. While most women had substantial benefit from the addition of abemaciclib as initial treatment, around one-third of women may not need a CDK 4/6 inhibitor as initial treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 9, 2017 Category: Cancer & Oncology Source Type: news

Extended AI Use Linked to CV Events and Bone Fractures Extended AI Use Linked to CV Events and Bone Fractures
There is growing interest in extending the use of adjuvant endocrine therapy in breast cancer, but the benefit vs risk for toxicity is not yet defined.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 29, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer
This video highlights trials studying the long-term impact of adjuvant tamoxifen and aromatase inhibitors for the treatment of patients with postmenopausal breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - August 25, 2017 Category: Cancer & Oncology Authors: Prudence A. Francis, MD Tags: Videos Breast Cancer Source Type: news

Using Molecular Tools to Guide Breast Cancer Treatment
This video examines the use of molecular diagnostics for guiding adjuvant endocrine therapy in patients with breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - August 22, 2017 Category: Cancer & Oncology Authors: Philippe L. Bedard, MD Tags: Breast Cancer Videos Breast Cancer Source Type: news

Papers of note in Science Translational Medicine 9 (402)
This week’s articles describe a way to prevent a major side effect of chemotherapy, paths of endocrine therapy resistance in breast cancer, and a new treatment for type 1 diabetes. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - August 15, 2017 Category: Science Authors: Ferrarelli, L. K. Tags: STKE Editors ' Choice Source Type: news

AstraZeneca ’s faslodex receives EU approval for advanced breast cancer treatment
The European Commission (EC) has approved AstraZeneca ’s faslodex (fulvestrant) for the treatment of oestrogen-receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 27, 2017 Category: Pharmaceuticals Source Type: news

' Right' Endocrine Therapy a Question in Youngest BC Patients'Right' Endocrine Therapy a Question in Youngest BC Patients
An analysis of the SOFT and TEXT trial results throws some light on the question of which endocrine therapy is best in young patients with breast cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 25, 2017 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news

T-DM1 in Early HER2+/HR+ Breast Cancer Offers Good Response Rates
T-DM1 administered for 12 weeks with or without endocrine therapy yields good rates of pathologic complete response in women with HER2-positive/hormone receptor –positive breast cancer, according to a new randomized trial. (Source: CancerNetwork)
Source: CancerNetwork - July 14, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

' Ultralow-Risk' Breast Cancers Can Skip Endocrine Therapy'Ultralow-Risk' Breast Cancers Can Skip Endocrine Therapy
' Ultralow-risk breast cancer'is a not commonly used term, but a new study suggests that patients with such cancers could receive less treatment.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 6, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Neoadjuvant Chemotherapy Improves Clinical Response in Breast Cancer
For premenopausal breast cancer patients, 24 weeks of neoadjuvant chemotherapy may yield a better clinical response than endocrine therapy. (Source: CancerNetwork)
Source: CancerNetwork - June 12, 2017 Category: Cancer & Oncology Authors: Mark Fuerst Tags: Conferences/ASCO Breast Cancer News Source Type: news

Palbociclib Might Reverse Acquired Breast Cancer Endocrine Resistance
Palbociclib alone and in combination with endocrine therapy offers clinical benefit among women with HR-positive, HER2-negative metastatic breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Breast Cancer News Source Type: news

Daily Texting Effectively Monitors Rx Adherence, Side Effects
Most patients with breast cancer taking endocrine therapy report intervention helpful in taking drugs (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 30, 2017 Category: Cancer & Oncology Tags: Gynecology, Nursing, Oncology, Pharmacy, Journal, Source Type: news

Predicting Response of Endocrine Therapy for Breast Cancer Predicting Response of Endocrine Therapy for Breast Cancer
Biomarkers, gene expression microarrays, circulating tumor cells, and circulating tumor DNA can help guide management of ER positive breast cancer.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 13, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Prognostic Tests for Prediction of Breast Cancer Recurrence Prognostic Tests for Prediction of Breast Cancer Recurrence
Which prognostic assay best predicts which patients may need adjuvant chemotherapy after endocrine therapy?Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 20, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Soy Tied To Longer Life After Breast Cancer
(Reuters Health) - - Eating more soy may be tied to better survival odds for many women with breast cancer and may not be harmful for patients treated with hormones, a new study suggests. Previous nutrition research has linked soy to a longer life, but prior studies have also suggested soy may help tumors spread by making hormone-based cancer treatments, or endocrine therapy, less effective. For the current study, researchers examined data on 6,235 U.S. and Canadian women with breast cancer. More than half of the women were followed for at least nine years. During the course of the study, women who ate the most foods conta...
Source: Healthy Living - The Huffington Post - March 7, 2017 Category: Consumer Health News Source Type: news

Adding a Statin to Endocrine Therapy Tied to Improved Breast Cancer Outcomes Adding a Statin to Endocrine Therapy Tied to Improved Breast Cancer Outcomes
Starting cholesterol-lowering therapy with adjuvant endocrine therapy was associated with clinical outcome for patients with ER-positive breast cancer in the BIG 1-98 clinical trial, researchers have found.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 14, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Disparities in Adjuvant Endocrine Therapy for Breast Cancer Identified Disparities in Adjuvant Endocrine Therapy for Breast Cancer Identified
In the U.S, minorities and women under 40 and over 80 frequently don't receive adjuvant endocrine therapy (AET) for breast cancer, putting their lives at risk, researchers say. (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 9, 2017 Category: Surgery Tags: Diabetes & Endocrinology News Source Type: news

Uneven Use of Hormone Therapy in Breast Cancer (CME/CE)
(MedPage Today) -- Significant variations in care for adjuvant endocrine therapy (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - February 2, 2017 Category: Endocrinology Source Type: news

Under and misuse of hormone therapy decreasing, but still high
(University of Chicago Medical Center) A nationwide cancer registry of almost one million patients treated for hormone-sensitive breast cancer shows that one out of six women who should have received post-surgical treatment known as adjuvant endocrine therapy did not get this recommended component of care, which can reduce the odds of recurrence. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 2, 2017 Category: Cancer & Oncology Source Type: news

FALCON Breast Cancer Trial: Who's Naive Here? FALCON Breast Cancer Trial: Who's Naive Here?
In the FALCON trial, fulvestrant improved PFS in ER+ metastatic breast cancer patients who were endocrine-therapy naive, but the trial failed to answer key clinical questions, says Dr Lidia Schapira.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 6, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
This research has been highlighted as a practice changing update by DynaMed Plus. It concludes that Fulvestrant has superior efficacy and is a preferred treatment option for patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not received previous endocrine therapy compared with a third-generation aromatase inhibitor, a standard of care for first-line treatment of these patients (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 4, 2017 Category: Consumer Health News Source Type: news

Stretching PFS in ER-Positive Metastatic Breast Cancer Stretching PFS in ER-Positive Metastatic Breast Cancer
In metastatic breast cancer, the current 14-16 months of PFS with endocrine therapy can be stretched to more than 20 months in the first-line setting, as explained in a plenary session at SABCS.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 21, 2016 Category: Consumer Health News Tags: Hematology-Oncology Article Source Type: news

Endocrine Therapy in Breast Cancer: Best Bet on Duration Endocrine Therapy in Breast Cancer: Best Bet on Duration
Dr Harold Burstein reviews the latest data on duration of adjuvant endocrine therapy in metastatic breast cancer, and provides much-needed recommendations on how to approach the topic with patients.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 19, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

One in Five Breast Cancer Patients Nonadherent to Endocrine Therapy
A study found that about 20% of women with breast cancer did not complete their prescribed endocrine therapy. (Source: CancerNetwork)
Source: CancerNetwork - December 16, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Breast Cancer News Source Type: news

Breast cancer patients fail to complete tamoxifen therapy
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, such as tamoxifen, according to researchers. (Source: Nursing Times)
Source: Nursing Times - December 14, 2016 Category: Nursing Source Type: news

Almost 20 percent of breast cancer patients fail to complete prescribed endocrine therapy
(European Society for Medical Oncology) Around 20 percent of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore. The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy were less likely to adhere to their medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 14, 2016 Category: Cancer & Oncology Source Type: news

B-52 Study: Estrogen Deprivation Bombs for Breast Ca (CME/CE)
(MedPage Today) -- Endocrine therapy fails to improve pre-surgery complete response rates (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - December 9, 2016 Category: Journals (General) Source Type: news